Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system
- 14 February 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in International Journal of Hematology
- Vol. 109 (4), 426-439
- https://doi.org/10.1007/s12185-019-02613-1
Abstract
We report the results of a multicenter observational study using the New TARGET system, in which the effectiveness and safety of tyrosine kinase inhibitors (TKIs) were evaluated in newly diagnosed chronic-phase chronic myeloid leukemia (CML) patients. A total of 506 patients were enrolled between April 2010 and March 2013. Median age was 56 (range 18–92) years; 35% of patients were females. As the first-line therapy, 139 (27.9%), 169 (33.9%) and 144 (28.9%) patients were treated with imatinib, nilotinib, and dasatinib, respectively. Five-year progression-free survival (PFS) and overall survival (OS) were 93.8% and 94.5%, respectively. The OS curve was significantly superior for patients treated with second-generation TKIs than imatinib (P = 0.0068), and an early molecular response (EMR) at 3 months (BCR-ABL1 < 10%) was detected in 328 of 377 patients evaluated for molecular response. The PFS curve was significantly superior for patients with EMR than without (P < 0.0001). Although 12 patients experienced vascular adverse events, no new safety issues were observed in patients with adverse events. The results of this observational study demonstrated that treating newly diagnosed CML-CP patients with TKI results in satisfactory and reliable outcomes.Keywords
This publication has 19 references indexed in Scilit:
- Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trialInternational Journal of Hematology, 2017
- Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final reportInternational Journal of Hematology, 2017
- Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid LeukemiaThe New England Journal of Medicine, 2017
- Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients TrialJournal of Clinical Oncology, 2016
- Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trialLeukemia, 2016
- Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitorsBlood, 2015
- Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET systemLeukemia Research, 2011
- Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaThe New England Journal of Medicine, 2010
- Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid LeukemiaThe New England Journal of Medicine, 2010
- Current and future perspectives on the TARGET system: the registration system for Glivec® established by the JSHInternational Journal of Hematology, 2008